Clinical aggression is determined by the anaerobic tumor metabolism driven by lactate dehydrogenase (LDHA) and the hypoxia-inducible factor HIF1alpha, as found in 175 breast cancer patients treated in a prospective study [45]. Here, HIF1A is linked to breast carcinoma.